Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ANTES

Financiado

Cerrado

Accelerating Neuromuscular Treatment Selection

Neuromuscular disorders (NMDs) affect an estimated 300.000 people in Europe and no therapies are available for these highly incapacitating and lethal disorders. In the last few years, this status quo has shifted dramatically with... ver más

31/08/2017

FUNDACION VASCA DE...

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

FUNDACION VASCA DE INNOVACION E INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 993K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACION VASCA DE INNOVACIO...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SCOPE-DMD Consortium for Products across Europe in Duchenne Muscular D... 21M€ Cerrado

circRNA4DMD Circular RNA Therapeutics for Duchenne Muscular Dystrophy 3M€ Cerrado

BIOIMAGE-NMD BIOIMAGE Neuromuscular Diseases 8M€ Cerrado

MAGIC Next-generation models and genetic therapies for rare neurom... 7M€ Cerrado

ENTRY-DM Interdisciplinary doctoral training on oligonucleotide-based... Cerrado

BIO-NMD Identifying and validating pre clinical biomarkers for diagn... 8M€ Cerrado

Líder del proyecto

FUNDACION VASCA DE INNOVACION E INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 993K€

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Neuromuscular disorders (NMDs) affect an estimated 300.000 people in Europe and no therapies are available for these highly incapacitating and lethal disorders. In the last few years, this status quo has shifted dramatically with the appearance of new RNA therapies targeting several of these disorders. Several clinical trials are currently underway but future development is being slowed due to several motives, mainly related to the requirement of personalised approaches for rarer mutations and to technical difficulties to evaluate the effects of these new therapies on relevant biological outcome measures. I have been awarded a fellowship to develop a platform to streamline drug development for NMDs by combining several resources: immortalized control and patients’ cells, specific antibodies and new imaging techniques to be able to measure immunostained cultured cells directly in plate format. Duchenne muscular dystrophy (DMD) will be the first NMD that will benefit from this approach. Several therapeutic approaches aim to restore dystrophin expression in DMD: gene therapy, stem cell therapy, nonsense mutation read-through and redirection of splicing with antisense oligonucleotides (AOs). A reliable quantitative method to measure dystrophin in cell culture is not yet available and this project will develop such system, which will not only speed up development of new AOs targeting less common mutations, but also be the stepping stone that we will use to expand the platform not only to find treatments to other NMDs, but also possibly as a diagnostic tool for some of them.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores